News & Updates

The novel plant-based polyphenol-rich compound, TOTUM-63, helps keep the lid on fasting plasma glucose (FPG) and other measures of glucose dysregulation in people with prediabetes and early type 2 diabetes (T2D), according to the pivotal phase II/III REVERSE-IT study.

Several barriers on the system and organizational levels disrupt the continuous implementation of SmartMoves, an evidence-based intensive health behaviour and lifestyle treatment (IHBLT) program, for children with obesity, a study has shown.

Low-intensity obesity interventions modestly reduce BMI in children, with one in five kids in the telephonic coaching condition achieving meaningful improvement in BMI z score, reports a recent study.

Use of the automated insulin delivery (AID) system delivers better glycaemic control in people with type 1 diabetes (T1D). However, switching to the Minimed 780G insulin pump system does not lead to notable changes in energy and nutrient intake in this population, according to a study.

Patients with type 2 diabetes (T2D) who initiated treatment with empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), and a glucagon-like peptide-1 receptor agonist (GLP-1RA) show reduced hospitalization for heart failure (HHF) and all-cause mortality risks relative to those treated with empagliflozin and dipeptidyl peptidase-4 inhibitors (DPP-4i), reports a study presented at EASD 2024.

Use of glucagon-like peptide-1 receptor agonists (GLP-1RA) among patients with type 2 diabetes (T2D) appears to have protective benefits against the development of glaucoma compared with exposure to other second-line antihyperglycaemic medications, according to a study.

Treatment with canagliflozin results in clinically meaningful reductions in glycated haemoglobin (HbA1c), when compared with placebo, in children and adolescents with type 2 diabetes (T2D), as shown by the results of a phase III study presented at EASD 2024.